Palvella Therapeutics, Inc.
PVLA
$156.13
-$0.42-0.27%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 61.78% | 31.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 44.09% | 31.41% | |||
| Operating Income | -44.09% | -31.41% | |||
| Income Before Tax | -38.71% | -24.01% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -38.71% | -24.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -38.71% | -24.01% | |||
| EBIT | -44.09% | -31.41% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -26.43% | -12.52% | |||
| Normalized Basic EPS | -26.42% | -12.54% | |||
| EPS Diluted | -26.43% | -12.52% | |||
| Normalized Diluted EPS | -26.42% | -12.54% | |||
| Average Basic Shares Outstanding | 9.71% | 10.20% | |||
| Average Diluted Shares Outstanding | 9.71% | 10.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||